Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Gilenya prescribing information
Editorial for JNV issue on PML.
Amyloid precursor protein at node of Ranvier modulates nodal formation.
MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells.
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Laquinimod - New Promising Treatment for Multiple Sclerosis
Patients with migraine do not have MRI-visible cortical lesions.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons.
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Arzerra receives approval in Japan
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
First NW patient to receive OHSU/VAMC-invented MS drug
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Confounding in association studies: month of birth and multiple sclerosis.

Pages